Company ProfilePremium

Arovella Therapeutics Limited

Company Profile Analysis

Ticker: ALA.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
Arovella Therapeutics Limited - Company showcase

Year Founded & Workforce

1999

Arovella Therapeutics Limited logo

Arovella Therapeutics Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Arovella Therapeutics Limited Overview

Arovella Therapeutics is a Melbourne-based, ASX-listed micro-cap biotechnology company. It became a clinical-stage company in calendar 2026 and is developing allogeneic ("off-the-shelf") cell therapies based on invariant Natural Killer T (iNKT) cells. The platform was in-licensed from Imperial College London in 2021, when SUDA Pharmaceuticals pivoted away from oro-mucosal drug delivery. The lead asset, ALA-101, is a CD19-directed CAR-iNKT cell therapy. Its US FDA IND was accepted in January 2026, it received Australian ethics approval in June 2026, and its first clinical batch was released in September 2026. First-patient dosing in a Phase 1 trial at The Alfred, Melbourne, is now guided for late October 2026. Behind it sits ALA-105, a CLDN18.2-targeted CAR-iNKT product for gastric and pancreatic cancer armoured with IL-12-TM technology, plus an emerging autoimmune strategy built on CD19 B-cell depletion. Arovella is one of very few companies globally advancing CAR-iNKT cells. It has no product revenue, held A$14.4m of cash at 30 June 2026, and went through a shareholder-driven board overhaul in April–May 2026.


Company's own description (FY2026 Annual Report, paraphrased)

The FY2026 Annual Report gives the principal activity as development of the company's iNKT cell platform for treatment of cancer. Management describes the platform as a next-generation allogeneic cell therapy with potential uses in blood cancers, solid tumours and selected autoimmune diseases. iNKT cells are a naturally occurring immune subset. They can kill cancer cells directly, reshape the tumour microenvironment and recruit other immune effectors. When engineered with a chimeric antigen receptor (CAR), they keep these innate and adaptive functions and carry a low risk of graft-versus-host disease (GvHD). That low GvHD risk is what allows donor-derived, batch-manufactured dosing.

The stated strategy is a modular CAR-iNKT platform. A proprietary, semi-automated, patent-protected and FDA-cleared manufacturing process is combined with interchangeable CAR targets (CD19, CLDN18.2, others under evaluation), armouring modules (IL-12-TM) and complementary technologies (allo-defence, iNKT agonists). The aim is to create barriers to entry through know-how, IP and trade secrets. Management frames value creation through three workstreams: blood cancers (ALA-101), solid tumours (ALA-105 plus IL-12-TM) and autoimmune disease (ALA-101 repurposed for B-cell depletion).

Independent characterisation

Arovella is a single-segment, pre-revenue, platform-stage cell-therapy developer whose investment value rests almost entirely on one binary near-term readout: first-in-human safety, pharmacokinetic and B-cell-depletion data from ALA-101. It does not manufacture in-house at GMP scale. Clinical material is produced through a contract manufacturer (Cell Therapies Pty Ltd, CTPL, in Melbourne), and the trial is run through a contract research organisation (SAPRO). That makes it an asset-light "virtual-plus" biotech with a small in-house research laboratory (Jumar Bioincubator). Its IP rests mostly on in-licensed rights (Imperial College London for iNKT and IL-12-TM; SparX Group for the CLDN18.2 binder; MD Anderson for DKK1), plus its own manufacturing-process patents and know-how.

The legacy SUDA business, which reformulated established drugs as oral sprays on the OroMist platform, is no longer strategically relevant. ZolpiMist (zolpidem oral spray) licensing generated small, irregular revenues through FY2023 and none in FY2026.

Business model and revenue model

DimensionCurrent state (FY2026)Intended future state
Product revenueNilCommercial sales of approved CAR-iNKT products, or royalties from a partner
Service revenueNilNot a stated strategy
Subscription revenueNilNot applicable
Licensing revenueNil in FY2026. A$136,000 revenue from contracts with customers in FY2025 (nature not specified in sources reviewed; historically ZolpiMist-related licensing)Out-licensing or regional partnering of ALA-101/ALA-105 (business development is an explicit board priority)
Non-operating incomeR&D Tax Incentive A$3.50m; interest income A$0.80m (FY2026)R&D Tax Incentive remains material while R&D is Australia-based

Value-chain position

Arovella sits at the discovery-to-early-clinical development stage of the oncology and cell-therapy value chain:

Upstream: academic licensors (Imperial College London; MD Anderson; SparX Group); lentiviral vector and reagent suppliers (the company had SEK-denominated liabilities at 30 June 2026, implying at least one Swedish vendor); healthy-donor blood collection.

Midstream (Arovella's own role): CAR design and integration, process development (Jumar laboratory), regulatory filings (FDA IND; TGA CTN), clinical strategy and translational science.

Outsourced midstream: GMP manufacturing (CTPL), clinical operations (SAPRO), and trial sites (The Alfred, with other Australian and New Zealand sites in start-up).

Downstream (future): marketing approval, reimbursement and commercialisation, most likely through a large-pharma partner given the company's scale.

Customer types and end-markets

There are no paying customers today. The prospective end-markets are:

  1. Haematological malignancies: relapsed/refractory CD19-positive non-Hodgkin lymphoma (NHL) and certain leukaemias. Payers would be hospital systems and national reimbursement bodies, with treating haematologists and cellular-therapy centres as prescribers.

  2. Solid tumours: CLDN18.2-positive gastric and gastro-oesophageal junction cancer, and pancreatic cancer.

  3. Autoimmune and neuro-immunological disease: B-cell-driven disorders. Stiff-person syndrome (SPS) is named explicitly as an example of high unmet need.

Strategy

Stated strategy (FY2026 Annual Report and Chair's letter, paraphrased)

  • Build a leading next-generation allogeneic cell therapy company on a modular CAR-iNKT platform that combines the proprietary manufacturing process with new CAR targets, armouring and complementary technologies.

Generate first-in-human proof-of-concept: with ALA-101 and use it to de-risk the whole platform, including solid tumours and autoimmune indications.

Three value-creation workstreams: blood cancer (ALA-101), solid tumours (ALA-105 plus IL-12-TM), autoimmune (ALA-101 B-cell depletion).

  • Board renewal focused on time to market, product development and business development, with the explicit aim of evaluating corporate and business-development initiatives to maximise shareholder value.

Continued in-licensing and assessment: of external technologies, including Baylor College of Medicine assets, additional CAR targets, allo-defence and agonists.

Strategic initiatives in the last 24 months (Oct 2024 – Oct 2026)

InitiativeDateDescriptionStatus
A$15m Phase 1 funding roundFeb–Mar 2025Replacement placement after the January 2025 investor defaultCompleted
Jumar in-house laboratoryFY2025–FY2026Research and process-development capability; A$0.42m PP&E additions in FY2025Operational
CRO appointment (SAPRO)29 Oct 2025Trial Pathway Partner for ALA-101 Phase 1Active
ALA-101 INDSubmitted 30 Dec 2025; accepted 29 Jan 2026FDA clearance of the manufacturing process and preclinical packageComplete
ANZ clinical start-upJan–Sep 2026TGA CTN; HREC approvals; The Alfred activationActive
Clinical Advisory Board expansionFY2026Prof. Cameron Turtle appointed; Dr Sam Fiorenza as Lead InvestigatorComplete
Autoimmune strategyFY2026Use Phase 1 B-cell-depletion data to support autoimmune expansion; SPS named as an examplePlanning and translational stage
ALA-105 preclinical programmeFY2026CLDN18.2 CAR validated; IL-12-TM armouring data; in vivo gastric and pancreatic modelsOngoing
Scientific conference presenceApr–May 2026Posters at AACR 2026 (San Diego, 20 Apr) and ISCT 2026 (Dublin, 7 May)Complete
Board strategic reviewFrom 4 May 2026Comprehensive review of technology, development strategy and growth opportunities; outcome presented in the 12 Aug 2026 webinarComplete; formal written outcome not detailed in sources reviewed
Investor-relations resetAug–Sep 2026Investor webinar; sponsored analyst coverage (Prenzler, 16 Sep 2026)Ongoing
ESG reporting17 Sep 20262026 ESG Report released to ASXReleased

Cost programmes

No formal cost-reduction programme with targets has been announced. The shift to an outsourced CFO and company-secretarial model (Bio101) and a three-person board reduces fixed governance overhead.

Medium-term guidance and targets

ItemGuidanceSource
First-patient dosing (ALA-101)Late October 2026 (revised from September 2026)1 Oct 2026 filing
Preliminary clinical dataEarly CY2027Corporate presentation / investor update summaries
Financial targetsNone. No revenue, margin or cash-burn targets have been issued—

Products & Services

There are no marketed products in the current strategic portfolio. The catalogue below lists each programme individually.

ALA-101 — CD19-directed allogeneic CAR-iNKT cell therapy (lead)

AttributeDetail
DescriptionHealthy-donor-derived iNKT cells transduced with a lentivirus encoding a CD19-targeting CAR. The cells also keep their invariant T-cell receptor, which recognises glycolipid-loaded CD1d, an antigen found on several cancer types. This gives a dual-targeting mechanism (CAR plus iTCR)
IndicationsRelapsed/refractory CD19+ non-Hodgkin lymphoma and certain leukaemia subtypes; potential expansion into B-cell-driven autoimmune disease (e.g. stiff-person syndrome)
Preclinical claimsPer the FY2026 Annual Report, ALA-101 outperformed conventional CAR-T cells against cell lines expressing both CD19 and CD1d, killed cancer cells rapidly and improved survival in mouse lymphoma and leukaemia models. Earlier Imperial data cited by Edison (2021) showed brain lymphoma eliminated in 13 of 18 CAR-iNKT-treated animals
ManufacturingDonor blood collection, iNKT isolation, lentiviral transduction, expansion to billions of cells, then vialling and cryopreservation. The process is semi-automated, patent-protected and cleared by the FDA within the IND. Clinical batches are made by CTPL in Melbourne
Regulatory statusFDA IND accepted 29 Jan 2026; TGA CTN acknowledged; HREC approvals (The Alfred, Bellberry) June 2026
Trial designPhase 1 first-in-human, open-label, dose escalation (to establish the maximum tolerated dose) followed by dose expansion/backfill. A single dose is given. Endpoints cover safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy, plus measurement of CD19+ B-cell depletion
SitesThe Alfred, Melbourne (lead; activated 7 Sep 2026). Further Australian and New Zealand sites are in start-up. US sites are possible under the IND in future
TimelineFirst clinical batch released 7 Sep 2026; first-patient dosing guided for late Oct 2026 (revised 1 Oct 2026 from September); preliminary data guided for early CY2027 (corporate presentation summary)
Licence sourceImperial College London (exclusive, global, oncology field)
Target customerHaematology and cellular-therapy treatment centres
Pricing modelNot publicly disclosed (pre-commercial)
Launch yearNot applicable (Phase 1)

ALA-105 — CLDN18.2-directed CAR-iNKT (solid tumours)

AttributeDetail
DescriptionCAR-iNKT cells targeting Claudin 18.2, a clinically validated tight-junction antigen expressed in gastric, gastro-oesophageal junction and pancreatic cancers
OriginCLDN18.2 binder licensed from SparX Group under a collaboration dated 10 Oct 2023
ArmouringDesigned to incorporate IL-12-TM. FY2026 data indicated that IL-12-TM improved the activity and durability of CAR-iNKT cells in relevant solid-tumour models
StagePreclinical. CAR functionality confirmed, with potent in vitro killing of CLDN18.2+ cells (preclinical data announced April 2026). Gastric and pancreatic in vivo models established and efficacy studies started; process development has begun at Jumar using a scaled-down manufacturing model
Next stepsIn vivo proof-of-concept with and without IL-12-TM, followed by IND-enabling activities (timing not guided)
Target customerOncology centres treating gastric and pancreatic cancer
Pricing model—

IL-12-TM armouring technology (enabling module)

AttributeDetail
DescriptionA membrane-tethered form of interleukin-12 expressed by engineered cells. It is designed to boost CAR-iNKT cell activity and persistence locally while limiting the systemic toxicity associated with free IL-12
SourceImperial College London (licence)
UseTo be incorporated into solid-tumour programmes, starting with ALA-105

ALA-104 — DKK1-directed CAR-iNKT (historic / deprioritised)

AttributeDetail
DescriptionCAR-iNKT targeting Dickkopf-1 (DKK1)-derived peptide presented on tumour cells, based on a monoclonal-antibody technology from MD Anderson
Licence termsGlobal exclusive; undisclosed upfront and milestones; single-digit royalties (Edison, FY2022)
Current statusAbsent from 2025–2026 company boilerplate and the FY2026 operating review. Status is not publicly disclosed and the programme appears deprioritised

Pipeline-expansion and complementary technology work (FY2026)

WorkstreamDetail
Baylor College of Medicine assetsContinuing discussions on in-licensing assets. Contract manufacturer CTPL separately referred to Arovella technologies targeting neuroblastoma and hepatocellular carcinoma as potential future products. Terms are not disclosed and no deal is confirmed
iNKT agonist combinationResearch collaboration evaluating an iNKT cell agonist with ALA-101 (counterparty not disclosed)
ALA-105 combination approachesResearch collaboration(s); counterparties not disclosed
Allo-defence technologiesEvaluation of approaches to protect allogeneic cells from host rejection (counterparties not disclosed)
Autoimmune translational workTesting on samples from patients with autoimmune disease to prioritise indications (e.g. SPS)

Legacy SUDA drug-delivery assets (non-core)

ProductDescriptionLast known status
ZolpiMistOral spray of zolpidem tartrate for short-term insomnia (spray version of the drug marketed as Ambien/Stilnox). Rights held outside North AmericaTGA-approved (29 Jul 2020); licensed to STADA Australia (launched FY2022); approved in Chile; Teva licence for Brazil, Mexico and Chile (2017). No FY2026 revenue; current commercial status not publicly disclosed
OroMist platformOro-mucosal delivery technology for cheeks, gums, tongue or floor of mouthNot an active strategic programme; status not publicly disclosed
Anagrelide oral sprayOro-mucosal reformulation of anagrelide (oncology)Not mentioned in FY2026 reporting; presumed discontinued (not publicly confirmed)

Financial Narrative

All figures are in AUD millions unless otherwise stated. FY2022–FY2026 revenue, net loss, year-end share price and market capitalisation come from the audited five-year table in the FY2026 Remuneration Report. FY2025–FY2026 detail comes from the FY2026 audited statements. FY2024 cash and equity come from the opening balances in the FY2026 statements of cash flows and changes in equity. FY2022–FY2023 cash comes from the Kalkine aggregator and is corroborated for FY2022 by Edison (net cash A$6.1m).

Income statement

Derivation notes: EBITDA = net loss + D&A − interest income. Operating loss = net loss − interest income; it includes the R&D Tax Incentive, which Arovella classifies within other income. Gross profit is not reported; the company has no cost of sales.

Margins: Gross, operating, EBITDA and net margins are not meaningful because revenue is nil or negligible. In FY2025, for example, the net loss was about 55 times revenue. Revenue CAGR (FY2022–FY2026) is not meaningful because revenue fell to zero.

Commentary. The loss trajectory has improved in each of the three years since its FY2023 peak of A$10.18m: down 14.1% in FY2024, 14.1% in FY2025 and 7.9% in FY2026. The FY2026 improvement did not come from cost cutting. Research costs fell by A$0.65m (−9.9%) as preclinical ALA-101 work tapered and spending shifted into clinical start-up. Interest income doubled to A$0.80m on the higher average cash balance after the March 2025 raise. The R&D Tax Incentive rose 5.9% to A$3.50m. These gains were partly offset by a 25.8% rise in employee benefits (team expansion at Jumar, plus severance-type effects around the CEO transition) and an 18.6% rise in other expenses, which plausibly reflects governance, legal and board-transition costs from the April–May 2026 requisition events (not separately quantified by the company). Share-based payments fell 43% to A$0.48m, helped by option lapses following director and CEO departures. Former CEO Baker's options line shows a negative A$32,120 reversal.

The FY2027 cost base should rise once patients are dosed, because clinical-trial, manufacturing-release and CRO costs scale with enrolment. The company disclosed R&D commitments of about A$1.89m at 30 June 2026.

Balance sheet

Commentary. The balance sheet is simple: almost entirely cash, no debt, no capitalised intangibles (all licence and R&D costs are expensed), and modest plant and equipment, mostly the Jumar laboratory fit-out added in FY2025 (A$0.42m of additions). Equity has fallen to A$14.15m against A$121.3m of cumulative capital raised, so about A$108.6m of accumulated losses has been absorbed since 1999. Arovella also carries a net unrecognised deferred tax asset of A$23.4m, including A$20.6m relating to revenue losses. At the 30% rate this implies about A$68.7m of carried-forward revenue tax losses, subject to continuity-of-ownership and similar-business tests. This is a contingent value item that the market does not price.

Cash flow

Quarterly burn (Appendix 4C): Net operating outflows were A$2.5m in the December 2025 quarter, with R&D and staff at 90% of outflows and 7.6 quarters of funding estimated at the time. In the June 2026 quarter they were A$2.3m, with R&D and staff at 89%, and the quarter closed with A$14.4m of cash.

Runway assessment (analyst): Gross quarterly outflows have run at A$2.3–2.8m, and the annual R&D Tax Incentive refund of about A$3.5m arrives in a lump. Before trial-enrolment cost escalation, that implies roughly 5–7 quarters of runway from 30 June 2026, i.e. funding into late CY2027. Once dose escalation is under way, a capital raise in the next 6–12 months is highly probable. The likely timing is after initial ALA-101 safety or B-cell-depletion data, if the share price allows. Note: this is an analyst estimate, not company guidance. The company's FY2026 going-concern note says only that cash is sufficient for current requirements and that the directors are confident of accessing further funding when required.

Ratios

Notes: ROIC, net debt/EBITDA and interest coverage are not meaningful because EBITDA is negative and there is no debt or interest expense. The cash conversion cycle is not meaningful because there is no revenue or inventory. FY2025 ROA would require FY2024 total assets, which are not disclosed in the sources reviewed.

Trends, inflections and drivers

  1. Funding-cycle dependence. Cash rises and falls with episodic placements: A$6.6m gross in FY2022, A$12.5m in March 2024 and A$15m in March 2025. The failed January 2025 placement, caused by a single investor's default, shows the fragility of micro-cap financing.

  2. Loss stabilisation at about A$7m a year, helped by Australia's 43.5% refundable R&D Tax Incentive, which offsets roughly 35–40% of eligible spend each year.

  3. Coming inflection: FY2027 should see a step-up in clinical costs. The FY2026 loss is therefore a floor for FY2027, not a run-rate.

  4. Dilution: Weighted shares rose 9.5% in FY2026 (1,097.2m to 1,201.1m), mainly reflecting the full-year effect of the March 2025 placement and 18.98m option exercises.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment Overview

SegmentContentsProducts / programmes

iNKT cell therapy development (sole segment)

All R&D, clinical, manufacturing-development, corporate and residual legacy licensing activity

ALA-101 (CD19 CAR-iNKT); ALA-105 (CLDN18.2 CAR-iNKT ± IL-12-TM); IL-12-TM armouring; ALA-104 (DKK1 CAR-iNKT, historic); allo-defence and agonist collaborations; legacy ZolpiMist/OroMist rights

Revenue by Segment and Segment Margins & Growth (%)

MetricFY2024FY2025FY2026

Segment revenue (AUD Mn)

0.0170.1360

Segment pre-tax result (AUD Mn)

-8.746-7.509-6.916

Revenue YoY growth (%)

-95.8700.0-100.0

Contribution to total revenue (%)

100100100

Group Structure

LayerComposition

Board

Three non-executive directors: David Williams (Chair), Mark Diamond, Dr Michael Thurn

Executive

Dr Nicole van der Weerden (Acting CEO); Lachie Mallia (CFO and Company Secretary, outsourced via Bio101)

Clinical Advisory Board

Includes Dr Salvatore Fiorenza (Lead Investigator) and Prof. Cameron Turtle (appointed FY2026); full membership not enumerated in sources reviewed

Scientific founder / adviser

Prof. Anastasios Karadimitris (Imperial College London), originally appointed via Imperial Consultants as Chair of the Scientific Advisory Board (FY2022)

Outsourced partners

CTPL (manufacturing); SAPRO (CRO); HLB Mann Judd (audit); Automic (registry)

Income Statement and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Revenue from contracts with customers (AUD Mn)

0.2960.4060.0170.1360

Other income – R&D Tax Incentive (AUD Mn)

———3.3033.498

Interest income (AUD Mn)

———0.3900.800

Research costs (AUD Mn)

———6.5225.873

Employee benefits expense (AUD Mn)

———2.2152.785

Share-based payment expense (AUD Mn)

———0.8450.482

Other expenses (AUD Mn)

———1.6501.956

Depreciation and amortisation (AUD Mn)

———0.1070.118

Operating loss excl. interest income (AUD Mn)

———-7.899-7.716

EBITDA (derived; AUD Mn)

———-7.792-7.598

Pre-tax loss (AUD Mn)

-8.621-10.181-8.746-7.509-6.916

Income tax expense (AUD Mn)

———00

Net loss (AUD Mn)

-8.621-10.181-8.746-7.509-6.916

Basic EPS (AUD cents)

———-0.68-0.58

Diluted EPS (AUD cents)

———-0.68-0.58

Dividends per share (AUD cents)

00000

Weighted average shares (m)

———1,097.21,201.1

Balance Sheet and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Cash and cash equivalents (AUD Mn)

6.0715.17512.71420.87714.353

Other current assets (AUD Mn)

———0.2930.304

Total current assets (AUD Mn)

———21.17014.657

Property, plant and equipment (AUD Mn)

——0.1310.4310.352

Total assets (AUD Mn)

———21.60015.010

Trade and other payables (AUD Mn)

———1.3610.718

Total liabilities (AUD Mn)

———1.5240.857

Short-term debt (AUD Mn)

00000

Long-term debt (AUD Mn)

00000

Net debt (AUD Mn; negative = net cash)

-6.071-5.175-12.714-20.877-14.353

Total equity (AUD Mn)

——11.22820.07614.152

Goodwill and intangibles (AUD Mn)

———00

Working capital (AUD Mn)

———19.67713.820

Issued capital (AUD Mn)

——104.296120.128121.270

Accumulated losses (AUD Mn)

——-95.506-102.837-108.622

Net tangible assets per share (AUD cents)

———1.691.17

Cash Flow

MetricFY2022FY2023FY2024FY2025FY2026

Payments to suppliers and employees (AUD Mn)

———-10.623-11.204

R&D tax incentive and grants received (AUD Mn)

———3.3033.498

Interest received (AUD Mn)

———0.3900.800

Operating cash flow (AUD Mn)

———-6.930-6.906

Capex – PP&E (AUD Mn)

———-0.413-0.039

Free cash flow (AUD Mn)

———-7.343-6.945

Equity proceeds, gross (AUD Mn)

———16.8100.507

Share issue costs (AUD Mn)

———-1.288-0.018

Net financing cash flow (AUD Mn)

———15.5220.489

Dividends paid (AUD Mn)

00000

Share buybacks (AUD Mn)

00000

Net change in cash (AUD Mn)

———8.160-6.458

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2025FY2026

ROE (%; net loss / average equity)

-48.0-40.4

ROA (%; net loss / average total assets)

—-37.8

Current ratio (x)

14.1817.51

Debt / equity (x)

00

Asset turnover (x; revenue / average assets)

—0

Revenue by Region

RegionFY2024FY2025FY2026

Total revenue – all regions, split not disclosed (AUD Mn)

0.0170.1360

Share Price and Market Valuation

MetricFY2022FY2023FY2024FY2025FY2026

Share price at 30 June (AUD)

0.0230.0500.1400.1000.062

Market capitalisation at 30 June (AUD Mn)

15.4142.50147.08118.8674.95

Shares on issue at 30 June (m)

——1,050.61,188.61,208.9

Share Price & Returns

HorizonReturnBasis

1-year

About -40% (Stockopedia, as of early Oct 2026); Market Index shows -46.9% relative to the ASX 200

Aggregators

3-year

About -6% (A$0.050 at 30 Jun 2023 to about A$0.047 on 7 Oct 2026)

Analyst calculation from company and Investing.com data

5-year

About -18% (A$0.057 at 30 Jun 2021 to about A$0.047)

Market Index year-end data; analyst calculation

52-week range

A$0.046 – A$0.103

Investing.com (7 Oct 2026)

Peak (fiscal year-end)

A$0.140 (30 Jun 2024); intra-period high about A$0.18–0.185 (late 2024)

Company; Market Index director-transaction prices

Valuation Multiples

MultipleArovellaComment

Market capitalisation

A$56.8m

1,208.85m shares

Enterprise value

About A$42.5m

Market cap less 30 Jun 2026 cash of A$14.35m; overstated once Q1 FY2027 burn is deducted

P/E

n/m

Loss-making

EV/EBITDA

n/m

Negative EBITDA

EV/Sales

n/m

Nil revenue

P/B

4.0x

Book equity A$14.15m

Price / net cash

4.0x

GuruFocus cited 3.0–3.6x at earlier prices

Capital Instruments

InstrumentNumberExercise price (AUD)Expiry

Ordinary shares

1,208,851,853——

Placement-attaching options

155,803,1750.150

24 May 2027

Employee/director options (various)

34,240,812

0.031–0.279

Dec 2026 – Oct 2030

Total options

190,043,987

WAEP 0.136

—

Analyst Conclusions

Management guidance

  • First-patient dosing of ALA-101 by late October 2026 at The Alfred.

  • Activation of additional Australian and New Zealand sites.

  • Preliminary clinical data (safety and B-cell depletion) in early CY2027.

  • Continued ALA-105 in vivo proof-of-concept and evaluation of autoimmune indications.

  • No financial guidance.

Consensus expectations

There is no meaningful consensus revenue or EPS forecast. The FY2027 loss is likely to exceed FY2026's A$6.9m as clinical costs scale. That is an analyst view, not guidance.

Bull case

  1. Valuation asymmetry. EV is about A$42m for a CAR-iNKT platform with an FDA-cleared process, GMP material released and a trial open. Clean safety and evidence of cell expansion or B-cell depletion in the first dose cohorts could plausibly re-rate the stock towards the A$118–147m market caps reached in FY2024–FY2025.

  2. Autoimmune optionality at no extra product cost. The Phase 1 measures CD19 B-cell depletion directly. A positive pharmacodynamic signal would open the best-funded segment of the cell-therapy market without a new IND-enabling package.

  3. Business-development-oriented board. The new directors bring licensing (Diamond), regulatory and development (Thurn) and capital-markets/M&A (Williams) experience. That raises the odds of a regional licence, an in-licence from Baylor, or a corporate transaction that crystallises value.

Bear case

  1. Financing overhang. Cash of A$14.35m against roughly A$7m of net annual burn before trial escalation means a raise is likely before or shortly after the first data, at prices near A$0.05. With 190m options mostly out of the money, the registry has been carrying losses since 2024 and dilution could be heavy.

  2. Execution and leadership risk. An acting CEO, a three-person board, eight director changes and two shareholder requisitions in one year, plus a one-month dosing slip, raise concern that strategic churn could distract from execution of a first-in-human trial.

  3. Modality and competitive risk. CAR-iNKT persistence in humans is unproven at scale. Even with clean safety, efficacy must stand against approved autologous CD19 CAR-Ts, bispecifics, and better-funded allogeneic and autoimmune competitors (Allogene, Caribou, Cabaletta, Kyverna, Nkarta).

Key catalysts and monitorables (next 12 months)

Expected timingCatalyst / monitorable
Late Oct 2026First patient dosed with ALA-101
30 Oct 2026AGM: director elections, remuneration report vote, possible new LTI grants
By 31 Oct 2026September-quarter 4C: cash balance and burn trajectory
Q4 CY2026 – Q1 CY2027Additional ANZ site activations; enrolment pace in dose escalation
Q4 CY2026 – H1 CY2027Permanent CEO appointment, or confirmation of van der Weerden
Early CY2027Preliminary safety, PK and B-cell-depletion data from first cohorts
H1 CY2027Capital raise (size, price, structure)
CY2027ALA-105 in vivo proof-of-concept readout; IND-enabling decision
CY2027Autoimmune indication selection (e.g. SPS) and regulatory pathway
Any timeBaylor in-licence or other business-development transaction
24 May 2027Expiry of 155.8m A$0.15 options (overhang removal)
OngoingR&D Tax Incentive refund for FY2026 (about A$3.5m expected, in line with FY2025–FY2026)

Analyst verdict

Arovella Therapeutics is a textbook example of an asymmetric, event-driven micro-cap biotech. On the evidence of its filings, the operating build is better than the share price suggests. Over 18 months the company filed and cleared a US IND, secured TGA and ethics approvals, manufactured and released GMP clinical material, and opened a reputable lead site. That is real progress for a company spending about A$7m a year net of the R&D Tax Incentive, and it rests on one of the very few CAR-iNKT platforms globally.

The market is nevertheless pricing the company at about A$42m of enterprise value, near its 52-week low. Three overlays explain this. The first is financing: cash of A$14.35m and an inevitable raise before meaningful data. The second is governance: a CEO exit forced by a requisition, an acting chief executive, a three-person board with negligible shareholdings, and option-based incentives without performance hurdles. The third is modality: there is no human CAR-iNKT persistence data yet, in a CD19 market crowded with approved and late-stage alternatives. The October 2026 dosing slip is small in isolation, but it reinforces the execution discount.

The investment case therefore turns on a short sequence. Arovella needs to dose cleanly, show safety, and show measurable cell expansion and B-cell depletion in early CY2027. If it does, the autoimmune and solid-tumour options gain credibility, the new board's business-development experience becomes valuable, and recapitalisation can happen at materially higher prices. If early cohorts show poor persistence or unexpected toxicity, the platform thesis weakens sharply and the equity becomes a cash-plus-licences option heading for heavy dilution.

Verdict: Speculative, high-risk, catalyst-driven. Monitor first-patient dosing, the September-quarter 4C, permanent CEO appointment and early-2027 pharmacodynamic data. A raise priced before data would be a clear negative signal; partnership-linked or post-data funding would be a positive one.


APPENDIX A — DATA DISCREPANCIES AND VERIFICATION FLAGS

ItemDiscrepancy / flag
Ticker / website in input listSUD.AX and sudapharma.com are obsolete; current identifiers are ALA and arovella.com
Name-change dateMarket Index records SUDA Pharmaceuticals until 22 Oct 2021; Yahoo/S&P says October 2021 (consistent)
HQ locationSome aggregators (Motley Fool/Morningstar, stoxray) still list Osborne Park, WA; the FY2026 Annual Report lists Preston, VIC
Employee countGuruFocus 44 vs Kalkine 0; not disclosed by the company
Current share priceInvesting.com A$0.047 (7 Oct 2026) vs Yahoo A$0.060; Investing.com used
Market Index status labelPage displayed a "HALTED SUSPENDED" label in October 2026; no supporting trading-halt announcement was located and Investing.com shows normal trading on 7 Oct 2026.
Substantial holdersMorningstar top-20 shows two holders above 5%; Market Index's substantial-holder database shows none lodged
Requisitioner identityNot disclosed in the ASX releases reviewed
Interim chair Feb–Apr 2026—
FY2022–FY2024 detailed financialsOnly revenue, net loss, year-end price and market cap verified from primary source; FY2022–FY2023 cash from aggregator
ALA-104 (DKK1) statusNot disclosed; absent from current pipeline descriptions
Quartr event labelsSome Quartr summaries are mislabelled by period (e.g. a "Q3 2026 TU" summary describes FY2025 metrics); primary filings used instead

APPENDIX B — PRINCIPAL SOURCES

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleAppointedBackground / prior rolesEducationShareholding

Mr David Williams

Non-Executive Chair (Chair from 4 May 2026)

28 Apr 2026

Long career in ASX capital markets, business development and M&A; associated with Kidder Williams (corporate advisory)

B.Com (Hons) and M.Econ (La Trobe); PhD research in finance (Univ. of Sydney); FAICD

200,000 shares (indirect, via Lawn Views Pty Ltd ATF Angela Williams Family Trust; on-market purchase 9 Jun 2026 at A$0.067)

Mr Mark Diamond

Non-Executive Director

28 Apr 2026

Former CEO, Antisense Therapeutics (now Percheron Therapeutics, ASX: PER); Biotech Advisor to Spark Plus and Locust Walk; record in licensing deals and partnerships

BSc (Monash); MBA (Macquarie)

Nil

Dr Michael Thurn

Non-Executive Director

28 Apr 2026

More than 25 years in biotech. Former MD/CEO of Neurizon Therapeutics (ASX: NUZ, formerly PharmAust); co-founder and Executive Director of MARP Therapeutics; COO and Executive Director of Botanix Pharmaceuticals; CEO of Mimetica and Spinifex Pharmaceuticals; former TGA regulatory reviewer

BAppSc (Hons) and PhD (UTS)

Nil

Executive Leadership Team

NameTitleTenureBackground

Dr Nicole van der Weerden

Acting Chief Executive Officer

Acting CEO since May 2026; previously Chief Operating Officer

BSc, BSc (Hons), PhD, MBA (Melbourne Business School) per Yahoo profile; three-month notice period

Mr Lachie Mallia

CFO and Company Secretary

Since 22 Jan 2026

Director of Bio101 (outsourced CFO, company-secretarial and transaction advisory services to healthcare); Chartered Accountant

Tony Macintyre

GM and CTO (per Yahoo profile)

—

Not disclosed; current status not confirmed in FY2026 Annual Report

“—” = not publicly disclosed.

Directors' Remuneration

NameCash salary/feesBonusNon-monetarySuperLSLOptions (SBP)Total

Michael Baker (MD/CEO; resigned 4 May 2026)

420,10995,15647,14330,0000-32,120560,288

Nicole van der Weerden (Acting CEO)

342,51654,42913,97630,0001,18161,859503,961

Elizabeth Stoner (Interim Chair; resigned 9 Feb 2026)

61,0070000061,007

Debora Barton (NED; resigned 4 May 2026)

54,6830000054,683

Gary Phillips (NED; resigned 9 Feb 2026)

39,658000034,03173,689

Andrew Nash (NED; 12 Nov 2025–4 May 2026)

31,0300000031,030

Michael Perry (NED; 28 Apr–4 May 2026)

1,241000001,241

David Williams (Chair)

15,113001,8140016,927

Mark Diamond (NED)

10,156001,2190011,375

Michael Thurn (NED)

11,3750000011,375

Total KMP

986,888149,58561,11963,0331,18163,7701,325,576

Directors' Remuneration (Annual)

KMP remuneration trendFY2025FY2026

Total KMP compensation (AUD Mn)

1.7751.326

Share-based payments to KMP (AUD Mn)

0.4740.064

CEO total – Michael Baker (AUD Mn)

0.7740.560

Governance Overview

AttributeStatus (post-May 2026)

Board size

3, all non-executive

Independence

All three are non-executive. The FY2026 Annual Report does not formally confirm independence assessments. Given the requisition context, investors should check the Appendix 4G and Corporate Governance Statement on arovella.com

Chair / CEO separation

Yes. The chair is non-executive and the CEO role is held on an acting basis by an executive who is not a director. Since Baker's resignation there is no managing director on the board

Committees

A Risk & Audit Committee met once in FY2026 (members Baker, Stoner, Barton, Phillips, all since departed). Current committee composition is not disclosed; with three directors, committee functions are likely exercised by the full board

FY2026 board meetings

13 held. Baker, Barton 13/13; Nash 8/8; Stoner, Phillips 6/7; Williams, Diamond, Thurn 6/6; Perry 1/1

Gender diversity

Board currently 0% female (previously included Dr Stoner and Dr Barton)

Board & Management Changes

DateChangeContext

1 Jul 2025

Dr Thomas Duthy resigns as Non-Executive Chair

Dr Elizabeth Stoner becomes Interim Chair

12 Nov 2025

Dr Andrew Nash appointed NED

Board strengthening ahead of IND

22 Jan 2026

Tim Luscombe replaced by Lachie Mallia as CFO and Company Secretary

Outsourced finance model via Bio101

9 Feb 2026

Stoner and Phillips resign

Chair vacancy; who chaired from February to April 2026 is not disclosed in sources reviewed

8–23 Apr 2026

Purported s249D requisition to appoint three directors; ruled invalid by the board; withdrawn

Requisitioner identity not disclosed in sources reviewed; nominees declined to meet the board

28 Apr 2026

Williams, Diamond, Thurn and Perry appointed

Company disclosures do not say whether these were the requisitioner's nominees

4 May 2026

Second s249D notice seeks removal of Baker and Perry; Baker, Nash, Barton and Perry resign; Williams becomes Chair

Board launches strategic review of platform, strategy and growth

May 2026

van der Weerden made Acting CEO

No permanent CEO search outcome disclosed as of October 2026

Major Shareholders

RankHolderShares% of capital
1

Biotech Capital Management

129,606,59710.72
2

Richard John Mann

68,487,6745.67
3

Netwealth Investments – Wrap Services A/C

33,595,5412.78
4

Netwealth Investments – Super Services A/C

32,619,8512.70
5

Ajava Holdings Pty Ltd

30,000,0002.48
6

UBS Nominees Pty Ltd

29,070,1962.40
7

Blackburne Capital Pty Ltd

27,268,0392.26
8

Legacy Asset Holdings Pty Ltd

22,362,8891.85
9

Dylide Pty Ltd

16,227,4811.34
10

M & M Stock One Pty Ltd

15,958,6681.32

Competitive Landscape

Key Competitors

CompetitorListingModality / assetOverlap with ArovellaRelative positioning

MiNK Therapeutics

Nasdaq: INKT

Allogeneic iNKT cells (agenT-797), unengineered and CAR-engineered

Closest iNKT pure-play

Further advanced clinically in iNKT (multiple trials), but cash-constrained; validates the modality

Kuur Therapeutics (formerly in Athenex)

Private / asset status uncertain after Athenex bankruptcy (2023)

CAR-iNKT (Baylor-derived; CD19 and GD2 programmes)

Direct CAR-iNKT precedent; Baylor link

Demonstrated the CAR-iNKT concept clinically; corporate disruption reduced competitive threat

Allogene Therapeutics

Nasdaq: ALLO

Allogeneic CAR-T (cema-cel, CD19)

Off-the-shelf CD19 cell therapy in lymphoma

Much better capitalised; pivotal-stage allogeneic CAR-T

Caribou Biosciences

Nasdaq: CRBU

CRISPR-edited allogeneic CAR-T (CD19)

Off-the-shelf CD19

Clinical data in LBCL; gene-editing approach to GvHD

Fate Therapeutics

Nasdaq: FATE

iPSC-derived NK/T cell therapies, incl. autoimmune

Off-the-shelf innate-cell platform; autoimmune pivot

Larger platform; iPSC manufacturing

Nkarta

Nasdaq: NKTX

Allogeneic CAR-NK (CD19), autoimmune focus

Innate-cell CD19 for autoimmune

Direct competitor for the autoimmune B-cell-depletion thesis

Cabaletta Bio

Nasdaq: CABA

Autologous CD19 CAR-T for autoimmune disease

CD19 autoimmune

Leading autoimmune CAR-T developer

Kyverna Therapeutics

Nasdaq: KYTX

Autologous CD19 CAR-T (KYV-101), incl. stiff-person syndrome

Directly overlaps the SPS example

Ahead clinically in SPS; sets the efficacy bar

Kite (Gilead) / Novartis / BMS / Autolus

Large-cap; Autolus Nasdaq: AUTL

Approved autologous CD19 CAR-T (Yescarta, Tecartus; Kymriah; Breyanzi; Aucatzyl)

Standard of care Arovella must improve on in access, cost and toxicity

Commercial incumbents

Imugene

ASX: IMU

Allogeneic CD19 CAR-T (azer-cel)

ASX-listed allogeneic CD19 peer

Closest ASX comparator; already reporting clinical data

Chimeric Therapeutics

ASX: CHM

CAR-T/CAR-NK (CLTX, CDH17)

ASX cell-therapy peer; solid tumours

Small-cap peer, also capital-constrained

CARsgen Therapeutics

HKEX: 2171

CLDN18.2 CAR-T (satri-cel)

Directly overlaps ALA-105 target

Late-stage in China; target validation and competitive bar

Astellas

TSE: 4503

Zolbetuximab (CLDN18.2 mAb, approved 2024)

CLDN18.2 gastric standard of care

Defines the CLDN18.2 treatment landscape

Peer Comparison FY2026

MetricArovella (ALA)MiNK Therapeutics (INKT)Imugene (IMU)Allogene (ALLO)

Modality

Allogeneic CAR-iNKT

Allogeneic iNKT

Allogeneic CD19 CAR-T plus oncolytics

Allogeneic CAR-T

Most advanced stage

Phase 1 (dosing pending)

Phase 1/2

Phase 1b

Pivotal Phase 2

Latest annual revenue

0 (FY2026, AUD)

———

Revenue growth

n/m

———

Margins

n/m

n/m (pre-revenue)

n/m

n/m

R&D intensity

Research costs 52% of opex (FY2026)

———

Cash (latest)

A$14.35m (30 Jun 2026)

———

Recent Developments

There have been no material litigation, guidance revisions of financial nature, or layoffs disclosed in the period.

Company Snapshot

1999

Founded

Preston, Australia

Headquarters

SWOT Analysis

Strengths

  • FDA IND accepted for ALA-101 (29 Jan 2026), including clearance of the manufacturing process, an external validation of CMC quality (ASX release).
  • Full ANZ regulatory stack in place: TGA CTN acknowledgement plus Alfred and Bellberry HREC approvals (25 Jun 2026).
  • Clinical material in hand: first GMP batch manufactured and released (7 Sep 2026).
  • Debt-free balance sheet with A$14.35m of cash and A$0.86m of total liabilities (30 Jun 2026).
  • Recurring non-dilutive funding: R&D Tax Incentive of A$3.50m (FY2026), up from A$3.30m (FY2025).
  • Credible clinical team: an experienced CAR-T clinician as Lead Investigator at a leading Melbourne transplant and cell-therapy centre, plus Prof. Cameron Turtle on the CAB.
  • Modular platform: the same lentiviral manufacturing process applies to any CAR (FY2026 AR), so ALA-105 and other follow-ons should need less incremental CMC work.

Weaknesses

  • No revenue (FY2026 nil) and accumulated losses of A$108.6m.
  • Leadership vacuum: acting CEO since May 2026; only three directors; former MD departed amid a shareholder requisition (4 May 2026 release).
  • Insider ownership around 0.08% (KMP shareholding 1.02m shares at 30 Jun 2026).
  • Timeline slippage: first dosing moved from September to late October 2026 (1 Oct 2026 filing).
  • Option overhang: 190.0m options (15.7% of shares), most far out of the money (WAEP A$0.136 vs A$0.047 share price), which signals the lost value of recent raises.
  • Heavy licence dependence: licence-agreement risk is the first-listed business risk (FY2026 AR risk 1.1).
  • Thin governance infrastructure: Risk & Audit Committee met once in FY2026; no performance hurdles on LTI options.

Opportunities

  • Early clinical data in early CY2027 could re-rate a stock trading near cash (EV about A$42m vs cash A$14.35m).
  • Autoimmune expansion using the same product and data package (B-cell depletion endpoint built into the Phase 1).
  • ALA-105 solid-tumour proof-of-concept in a validated target (CLDN18.2), with IL-12-TM armouring data already generated.
  • In-licensing from Baylor College of Medicine (talks disclosed FY2026) to widen the pipeline into neuroblastoma or HCC.
  • Partnering or regional licensing of ALA-101/ALA-105. The board has explicit business-development experience (Diamond: licensing; Williams: M&A).
  • Tax-loss value: about A$20.6m of unrecognised revenue-loss DTA.
  • US expansion under the open IND to accelerate enrolment.

Threats

  • Clinical failure or toxicity in first-in-human dosing; the company notes drug development typically takes 7–11 years from clinical entry.
  • Financing risk and dilution: the January 2025 placement collapsed on an investor default; the share price is near its 52-week low (A$0.046–0.103 range).
  • Competitive crowding in CD19 (approved autologous CAR-Ts, bispecifics, allogeneic CAR-T) and autoimmune cell therapy (Cabaletta, Kyverna, Nkarta, Fate).
  • Activist and governance instability: two s249D notices in four weeks (April–May 2026).
  • Key-person risk concentrated in the acting CEO and the outsourced CFO.
  • Modality risk: limited human evidence on CAR-iNKT persistence; MiNK's progress (or setbacks) will colour sentiment.
  • FX exposure: USD, GBP and SEK supplier costs.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
24 May 2025Grant of placement-attaching options (A$0.15, expiring 24 May 2027); quotation sought for 39.9m optionsAdds overhang. About 155.8m A$0.15 options now expire on that date
30 Jun 2025FY2025 year-end: cash A$20.88mPeak cash balance
1 Jul 2025Chair Dr Thomas Duthy resignsStart of board instability
1–7 Jul 2025Option grants to Baker, van der Weerden and staff (A$0.1425–0.1439)Routine LTI
22 Aug 2025FY2025 Annual Report: net loss A$7.51mResults
7 Aug – 24 Nov 2025Option exercises (incl. Baker 1.62m on 13 Oct; Barton 1.01m on 12 Nov; Stoner 1.16m on 24 Nov)Insider exercises, mostly ahead of later exits
14 Sep 20251.5m options lapseMinor capital-structure change
29 Oct 2025SAPRO appointed CROTrial start-up begins
30 Oct 2025AGM; options granted to Phillips (A$0.138)Governance
12 Nov 2025Dr Andrew Nash appointed NEDBoard addition
30 Dec 2025IND submitted to FDAKey regulatory filing
22–23 Jan 2026Q2 FY2026 4C: cash A$19.4m; outflow A$2.5m; 7.6 quarters of fundingLiquidity update
22 Jan 2026CFO and Company Secretary change to Lachie MalliaFinance function outsourced
29 Jan 2026FDA accepts ALA-101 INDClinical-stage inflection
9 Feb 2026Interim Chair Stoner and NED Phillips resignBoard attrition
13–19 Feb 2026Option exercises (6m shares)Minor dilution
19 Feb 2026H1 FY2026 resultsInterim
10 Apr 2026Purported s249D requisition (three-director appointment) disclosedActivist challenge
20 Apr 2026AACR 2026 poster; preclinical CLDN18.2 CAR dataALA-105 validation
20 Apr 20262m options granted (A$0.125)Routine
22 Apr 2026Board declares requisition invalid; nominees decline to meetGovernance dispute
23 Apr 2026Requisition withdrawnDe-escalation
28 Apr 2026Four new NEDs appointed (Williams, Diamond, Thurn, Perry)Board reconstitution
4 May 2026New s249D notice; CEO Baker resigns; Nash, Barton and Perry resign; Williams Chair; strategic review launchedLeadership change; key-person risk
7 May 2026ISCT 2026 poster (Dublin); corporate presentationScientific visibility
May 2026van der Weerden appointed Acting CEOContinuity of operations
9 Jun 2026Chair Williams buys 200,000 shares on market at A$0.067Modest insider buying
25 Jun 2026Ethics approval; The Alfred lead site; Fiorenza Lead InvestigatorFinal regulatory gate
30 Jun 2026FY2026 year-end: cash A$14.35mLiquidity
27 Jul 2026Q4 FY2026 4C: outflow A$2.3m; first clinical batch in release testing; Prof. Turtle joins CABOperational update
11–12 Aug 2026Investor webinar on strategic-review outcomeStrategy communication
20 Aug 2026FY2026 Appendix 4E and Annual Report: net loss A$6.92m; share price fell about 16% on the day (A$0.064 to A$0.054, InvestSMART)Results
7 Sep 2026First clinical batch released; The Alfred activatedClinical readiness
16 Sep 2026Prenzler sponsored analyst reportCoverage
17 Sep 20262026 ESG Report released; shares down about 8.5% on the day (A$0.059 to A$0.054)Disclosure
1 Oct 2026Screening update; first dosing slips to late October 2026Timeline slippage (about one month)
7 Oct 2026Share price about A$0.047, near the 52-week low of A$0.046Market scepticism
30 Oct 2026 (scheduled)Annual General MeetingFirst AGM under the new board; remuneration and director-election votes

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

4 charts
Income Statement: Revenue & Gross Profit: Revenue from contracts with customers fell from AUD 0.3 Mn in FY2022 to AUD 0 Mn in FY2026.
Arovella Therapeutics Limited — Income Statement: Revenue & Gross Profit
Series (AUD Mn)FY2022FY2023FY2024FY2025FY2026
Revenue from contracts with customers0.30.400.10

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.